A Caltech Library Service

Mechanism of Action of Risuteganib for Retinal Diseases through Protection of Retinal Pigment Epithelium (RPE) and Enhancement of Mitochondrial Functions

Zhou, Dan and Chwa, Marilyn and Shao, Zixuan and Koo, Jin Mo and Park, John Y. and Karageozian, Hampar L. and Karageozian, Vicken H. and Kenney, Cristina M. and Kornfield, Julia A. (2020) Mechanism of Action of Risuteganib for Retinal Diseases through Protection of Retinal Pigment Epithelium (RPE) and Enhancement of Mitochondrial Functions. Investigative Ophthalmology and Visual Science, 61 (7). Art. No. 4949. ISSN 0146-0404.

[img] PDF - Published Version
Creative Commons Attribution Non-commercial No Derivatives.


Use this Persistent URL to link to this item:


Purpose : Risuteganib is a novel synthetic peptide that has advanced through Phase II clinical trials, showing promising efficacy in retinal diseases, including dry age-related macular degeneration (AMD) and diabetic macular edema (DME). This study is to explore the mechanism of action (MOA) of risuteganib by uncovering its functional target(s) and the associated cell layer. Methods : Fluorescent staining of mouse and rat retinal cryo-sections was performed with risuteganib-dye conjugates and compared with control peptide. Protective effects against oxidative stress was studied in ARPE-19 cell line challenged with tert-Butyl Hydroperoxide (tBHP) using WST-1 assay and Caspase 3/7 apoptosis assay. Mitochondrial bioenergetics were measured using Seahorse XF cell mito stress test. Results : Peptide-dye staining of animal retinal tissue indicated preferential localization of risuteganib in the RPE layer. 24hr risuteganib pretreatment significantly rescued ARPE-19 cells from tBHP-induced oxidative stress in WST-1 assay (p<0.05) and Caspase 3/7 apoptosis assay (p<0.01). Seahorse bioenergetics measurement of ARPE-19 cells showed that risuteganib dose-dependently enhanced mitochondrial basal, maximal and ATP-related respirations of RPE cells. Conclusions : Oxidative stress is one of the hallmarks of retinal diseases AMD and DME, and is associated with impaired RPE function. The observations of preferential binding to RPE layers in retina and the protection of mitochondrial function in RPE cells against oxidative stress in vitro, suggest that the clinically observed therapeutic effect of risuteganib in dry AMD and DME may be associated with supporting RPE cells and maintaining mitochondrial stability and function. Such a novel MOA of risuteganib could lead to new strategies for treatment of retinal diseases.

Item Type:Article
Related URLs:
URLURL TypeDescription
Kornfield, Julia A.0000-0001-6746-8634
Additional Information:© 2020 Association for Research in Vision and Ophthalmology. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Issue or Number:7
Record Number:CaltechAUTHORS:20200921-110447558
Persistent URL:
Usage Policy:No commercial reproduction, distribution, display or performance rights in this work are provided.
ID Code:105456
Deposited By: Tony Diaz
Deposited On:21 Sep 2020 19:01
Last Modified:21 Sep 2020 19:01

Repository Staff Only: item control page